- Home
- NXDT vs RAPT Comparison
NXDT vs RAPT Comparison
Compare NXDT & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- RAPT
- Stock Information
- Founded
- NXDT 2012
- RAPT 2015
- Country
- NXDT United States
- RAPT United States
- Employees
- NXDT N/A
- RAPT N/A
- Industry
- NXDT Investment Managers
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NXDT Finance
- RAPT Health Care
- Exchange
- NXDT Nasdaq
- RAPT Nasdaq
- Market Cap
- NXDT 223.1M
- RAPT 194.2M
- IPO Year
- NXDT N/A
- RAPT 2019
- Fundamental
- Price
- NXDT $3.45
- RAPT $13.20
- Analyst Decision
- NXDT
- RAPT Buy
- Analyst Count
- NXDT 0
- RAPT 5
- Target Price
- NXDT N/A
- RAPT $33.60
- AVG Volume (30 Days)
- NXDT 133.6K
- RAPT 115.3K
- Earning Date
- NXDT 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- NXDT 9.66%
- RAPT N/A
- EPS Growth
- NXDT N/A
- RAPT N/A
- EPS
- NXDT 0.99
- RAPT N/A
- Revenue
- NXDT N/A
- RAPT N/A
- Revenue This Year
- NXDT N/A
- RAPT N/A
- Revenue Next Year
- NXDT N/A
- RAPT N/A
- P/E Ratio
- NXDT $6.41
- RAPT N/A
- Revenue Growth
- NXDT N/A
- RAPT N/A
- 52 Week Low
- NXDT $5.89
- RAPT $5.67
- 52 Week High
- NXDT $13.07
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- NXDT 35.19
- RAPT 64.26
- Support Level
- NXDT $3.50
- RAPT $11.19
- Resistance Level
- NXDT $3.86
- RAPT $13.66
- Average True Range (ATR)
- NXDT 0.26
- RAPT 0.81
- MACD
- NXDT -0.01
- RAPT 0.18
- Stochastic Oscillator
- NXDT 19.72
- RAPT 87.20
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.